buparlisib | Buparlisib

Keyword	CPC	PCC	Volume	Score	Length of keyword
buparlisib	0.9	0.1	4863	75	10

Keyword	CPC	PCC	Volume	Score
buparlisib	0.58	0.7	5085	51
buparlisib fda approval	0.65	0.8	2977	4
buparlisib novartis	1.53	0.1	8782	1
buparlisib head and neck cancer	0.84	0.8	8326	26
buparlisib_1873	1.06	0.4	3365	81
buparlisib bkm120	1.99	0.3	7803	45
buparlisib hydrochloride	0.95	0.2	4234	81
buparlisib fda	0.75	1	3291	73
buparlisib mice	0.95	0.5	7931	17
buparlisib mechanism of action	0.42	0.1	7226	50

Search Results related to buparlisib on Search Engine

Buparlisib - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Buparlisib

WEBBuparlisib (codenamed AN2025 and BKM120) is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. Buparlisib was under investigation as a treatment for advanced breast cancer but was abandoned due to negative results.

DA: 51 PA: 16 MOZ Rank: 69

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K …
biomedcentral.com

https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-020-01354-y

WEBNov 2, 2020 · Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety and efficacy of buparlisib in patients with metastatic triple-negative breast cancer. This was a single-arm phase 2 study enrolling patients with triple-negative metastatic breast cancer.

DA: 97 PA: 5 MOZ Rank: 81

FDA approves first PI3K inhibitor for breast cancer | FDA
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer

WEBToday, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and...

DA: 55 PA: 12 MOZ Rank: 61

The BURAN Study of Buparlisib in Patients With Recurrent or …
clinicaltrials.gov

https://classic.clinicaltrials.gov/ct2/show/NCT04338399

WEBApr 8, 2020 · The BURAN study is a randomized, open-label phase III study to assess the treatment effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1 ...

DA: 94 PA: 14 MOZ Rank: 46

Research update on the anticancer effects of buparlisib (Review)
spandidos-publications.com

https://www.spandidos-publications.com/10.3892/ol.2021.12527

WEBFeb 9, 2021 · Buparlisib has been confirmed to have a clinical effect in patients with solid tumors and hematological malignancies. A global, phase II clinical trial with buparlisib and paclitaxel in head and neck squamous cell carcinoma has now been completed, with a manageable safety profile.

DA: 23 PA: 90 MOZ Rank: 19

Share this article - PR Newswire
prnewswire.com

https://www.prnewswire.com/news-releases/adlai-nortye-announces-first-patient-dosed-in-global-phase-iii-clinical-trial-of-buparlisib-an2025-in-combination-with-paclitaxel-for-the-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-301269338.html

WEBApr 15, 2021 · Buparlisib (AN2025) is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors. In the global phase II clinical trial for...

DA: 42 PA: 99 MOZ Rank: 80

Buparlisib in Treating Patients With Relapsed or ... - Mayo Clinic
mayo.edu

https://www.mayo.edu/research/clinical-trials/cls-20118592

WEBBuparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma - Mayo Clinic. Overview. Study type Interventional. Study IDs. About this study. This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned or does not respond to treatment.

DA: 96 PA: 7 MOZ Rank: 35

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical …
prnewswire.com

https://www.prnewswire.com/news-releases/adlai-nortye-announces-first-patient-dosed-in-phase-ia-clinical-trial-of-an2025-and-an0025-in-combination-with-atezolizumab-for-advanced-solid-tumors-301370899.html

WEBSep 8, 2021 · AN2025 (buparlisib) is an oral pan-PI3K inhibitor that targets all class I PI3K isoforms and is active in both hematologic malignancies and solid tumors.

DA: 53 PA: 38 MOZ Rank: 94

Buparlisib is a brain penetrable pan-PI3K inhibitor - Nature
nature.com

https://www.nature.com/articles/s41598-018-29062-w.pdf

WEBBuparlisib is a novel pan-PI3K inhibitor that is currently in clinical development for various cancers, including primary and secondary brain tumours. Importantly however, earlier studies have...

DA: 37 PA: 35 MOZ Rank: 2

A phase 2 trial of buparlisib in patients with platinum‐resistant
wiley.com

https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.33071

WEBAug 7, 2020 · This trial explored buparlisib, an inhibitor of the pathway, in patients with heavily pretreated metastatic UC. Although the drug was found to have modest efficacy, with 6 patients experiencing stable disease and 1 patient achieving a partial response at 8 weeks on therapy, significant side effects also were observed.

DA: 10 PA: 13 MOZ Rank: 96